玻璃体腔注射阿柏西普2 mg、阿柏西普8 mg与法瑞西单抗后短期眼压变化:一项前瞻性比较研究
这项前瞻性观察研究纳入90例年龄相关性黄斑变性或糖尿病性黄斑水肿患者,分三组分别接受阿柏西普2 mg、阿柏西普8 mg或法瑞西单抗玻璃体腔注射。三组在注射后30秒均出现显著眼压升高,平均升幅分别为41.47±12.95 mm Hg、43.46±8.97 mm Hg和32.19±11.06 mm Hg;至15分钟时各组平均眼压均恢复至正常范围。法瑞西单抗初始眼压峰值较小,但整体眼压变化特征在不同药物间相当。
要点
- 三组注射后30秒眼压均显著升高,法瑞西单抗升幅32.19±11.06 mm Hg小于两种阿柏西普制剂。
- 至注射后5分钟组间眼压差异无统计学显著,至15分钟各组平均眼压均恢复至正常范围。
- 法瑞西单抗初始眼压峰值较小,但在5分钟和15分钟时该差异无统计学显著。
核心结论
- 玻璃体腔注射阿柏西普8 mg和法瑞西单抗后可见短暂眼压升高,趋势与阿柏西普2 mg相似。
- 初始眼压升高在15分钟内恢复正常,法瑞西单抗初始峰值较低但不同药物整体眼压变化特征相当。
研究设计与样本
- 这是一项观察性、前瞻性研究,纳入90例年龄相关性黄斑变性或糖尿病性黄斑水肿患者,分为三组分别接受阿柏西普2 mg、阿柏西普8 mg或法瑞西单抗玻璃体腔注射。
- 使用iCare IC200眼压计在注射前(T0)及注射后30秒(T1)、5分钟(T2)、15分钟(T3)测量眼压,主要结局为四个时间点组内和组间眼压变化,并记录需前房穿刺的短暂视力丧失发生率。
主要发现
- 所有组在T1均出现显著眼压升高,平均眼压升幅为阿柏西普2 mg组41.47±12.95 mm Hg、阿柏西普8 mg组43.46±8.97 mm Hg、法瑞西单抗组32.19±11.06 mm Hg。
- 至T2时组间眼压差异无统计学显著,至T3时各组平均眼压均恢复至正常范围。
- 法瑞西单抗初始眼压峰值小于两种阿柏西普制剂,但该差异在T2和T3时无统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. METHODS: This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab. IOP was measured using an iCare IC200-tonometer preinjection (T0) and at 30 s (T1), 5 min (T2) and 15 min (T3) postinjection. Primary outcomes included IOP changes at the four time points within and between treatment groups. The incidence of transient visual loss requiring paracentesis was recorded. RESULTS: All groups experienced a significant IOP increase at T1, with mean IOP increase being 41.47±12.95 mm Hg for aflibercept 2 mg, 43.46±8.97 mm Hg for aflibercept 8 mg and 32.19±11.06 mm Hg for faricimab. By T2, IOP differences were not significant, and by T3, mean IOP returned within normal limits across all groups. Faricimab showed a smaller initial IOP spike than both aflibercept formulations, but this difference was not statistically significant at T2 and T3. CONCLUSION: Transient IOP spikes are observed post-IVT of aflibercept 8 mg and faricimab, with similar trends to aflibercept 2 mg. The initial IOP elevation normalised within 15 min. Faricimab had a lower initial spike, but overall IOP profiles were comparable across different agents.
引用
- Paris A, Volpe G, Perruchoud-Ader K, et al. Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study. Br J Ophthalmol. 2025. PMID: 39532510. doi:10.1136/bjo-2024-326053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。